Literature DB >> 12915395

Pyruvate shuttle in muscle cells: high-affinity pyruvate transport sites insensitive to trans-lactate efflux.

Raymond Mengual1, Kaoukib El Abida, Nassima Mouaffak, Michel Rieu, Michele Beaudry.   

Abstract

The specificity of the transport mechanisms for pyruvate and lactate and their sensitivity to inhibitors were studied in L6 skeletal muscle cells. Trans- and cis-lactate effects on pyruvate transport kinetic parameters were examined. Pyruvate and lactate were transported by a multisite carrier system, i.e., by two families of sites, one with low affinity and high capacity (type I sites) and the other with high affinity and low capacity (type II). The multisite character of transport kinetics was not modified by either hydroxycinnamic acid (CIN) or p-chloromercuribenzylsulfonic acid (PCMBS), which exert different types of inhibition. The transport efficiency (TE) ratios of maximal velocity to the trans-activation dissociation constant (Kt) showed that lactate and pyruvate were preferentially transported by types I and II sites, respectively. The cis-lactate effect was observed with high Ki values for both sites. The trans-lactate effect on pyruvate transport occurred only on type I sites and exhibited an asymmetric interaction pattern (Kt of inward lactate > Kt of outward lactate). The inability of lactate to trans-stimulate type II sites suggests that intracellular lactate cannot recruit these sites. The high-affinity type II sites act as a specific pyruvate shuttle and constitute an essential relay for the intracellular lactate shuttle.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12915395     DOI: 10.1152/ajpendo.00034.2003

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  1 in total

1.  Breathing 100% O2 has no Effect on Blood Lactate Concentration During a Short Passive Recovery from Exhaustive Exercise.

Authors:  Bartholomew Kay; Hayden Walker; Dominic Barnao; Iain Graham; Stephen Stannard; R Hugh Morton
Journal:  J Sports Sci Med       Date:  2005-06-01       Impact factor: 2.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.